Cerus CORP

Cerus Corporation reported a 10% year-over-year increase in product revenue to $57.4 million for the second quarter of 2026, and raised the lower end of its full-year product revenue guidance.

Cerus Corporation announces William Greenman's transition from CEO to Executive Chairman, with updated compensation and service terms.

Cerus Corporation has entered into new credit agreements, amending and restating its existing term and revolving loan facilities, providing up to $65 million in term loans and $30 million in revolving credit.

Cerus Corporation's stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing share availability, and ratified the appointment of Ernst & Young LLP.

Cerus Corporation has implemented a new severance plan for key executives to provide standardized benefits in the event of termination following a change in control.

Cerus Corporation announces a leadership transition with Vivek Jayaraman promoted to President and CEO, effective July 1, 2026, while William Obi Greenman transitions to Executive Chairman.

Cerus Corporation reports increased product revenue in Q2 2026, driven by higher sales volumes for its INTERCEPT Blood System kits and IFC, while net loss narrows.

Cerus Corporation reported a 23% increase in total revenue to $59.9 million for the first quarter of 2026, driven by growth in platelet and IFC product sales.

Cerus Corporation reported a significant reduction in net loss for the third quarter and first nine months of 2025, driven by robust product and government contract revenue increases, despite ongoing development challenges for its red blood cell system and increased operating expenses.

Cerus Corporation reported increased product and government contract revenue for Q2 2025, but faced a regulatory setback for its red blood cell system and a shift to negative operating cash flow.

Cerus Corporation announces a 13% increase in total revenue for the first quarter of 2025, driven by growth in U.S. platelet kit sales.

Cerus Corporation's third quarter results show an increase in product revenue but a decrease in government contract revenue, with ongoing development of the red blood cell system.

Cerus Corporation saw product and government contract revenue increase in 2025, leading to a reduction in net loss, despite ongoing regulatory challenges for its red blood cell system and significant debt obligations.

Cerus Corporation's 10-K filing outlines the company's efforts in developing and commercializing its INTERCEPT Blood System, including progress, risks, and financial performance.

Cerus Corporation's 10-K filing details its capital stock, potential takeover defenses, and regulatory environment, highlighting the complexities of its business.

Vivek K Jayaraman, Chief Executive Officer of Cerus Corp, sold 16,666 shares of common stock on July 16, 2026 for $3.16 per share.

Cervus Corp. Chief Financial Officer Kevin Dennis Green reported transactions involving common stock, including the acquisition of 63,600 shares and the sale of 33,676 shares.

Cerus Corporation's Chief Operating Officer, Vivek K. Jayaraman, has reported transactions involving the acquisition of 80,000 common shares and the grant of performance rights, alongside the sale of 42,359 shares.

Cerus Corporation's Chief Legal Officer, Chrystal Jensen, reported a sale of 24,329 shares of common stock on June 30, 2026, for a weighted average price of $2.94.

Cerus Corporation reports insider William Greenman sold 101,919 shares of common stock on June 30, 2026, as part of a pre-arranged trading plan.

Director Eric Bjerkholt reduced his direct holdings in Cerus Corp by selling 20,454 shares at a price of $2.60 per share.

Cerus Corporation announces its 2026 Annual Meeting of Stockholders, to be held virtually on June 2, 2026, with key proposals including director elections and equity plan amendments.

Cerus Corporation has issued a supplement to its 2025 Annual Meeting proxy statement to correct an overstated number of outstanding stock options and to urge stockholders to approve its Amended and Restated 2024 Equity Incentive Plan, vital for talent attraction and retention.

Cerus Corporation's upcoming annual meeting on June 3, 2025, will include votes on director elections, amendments to equity incentive and employee stock purchase plans, executive compensation, and auditor ratification.

Cerus Corporation is asking stockholders to approve an amendment to its 2024 Equity Incentive Plan to increase the number of shares available for issuance by ten million.

Cerus Corporation's upcoming annual meeting on June 5, 2024, will address director elections, amendments to equity incentive and employee stock purchase plans, executive compensation, and auditor ratification.

Cerus Corporation is holding its annual meeting on June 5, 2024, to vote on director elections, an equity incentive plan, an employee stock purchase plan amendment, executive compensation, and auditor ratification.

The Vanguard Group has reported a 0% beneficial ownership in Cerus Corp following an internal realignment, with subsidiaries now reporting separately.

Soleus Capital Master Fund and related entities, including Guy Levy, have reported a passive beneficial ownership of 5.1% in Cerus Corporation, totaling 9,828,700 shares.

Baker Bros. Advisors and its principals have filed an Amendment No. 12 to their Schedule 13G, disclosing a continued 5.2% beneficial ownership in Cerus Corporation as of September 30, 2025.

Baker Bros. Advisors and its principals have filed an Amendment No. 11 to their Schedule 13G, reporting continued beneficial ownership of 6.7% to 6.8% of Cerus Corporation's common stock.

ARK Investment Management LLC and Catherine D. Wood have jointly reported a beneficial ownership of 10.05% in Cerus Corp's Common Stock, totaling 19,207,604 shares.

ARK Investment Management LLC has filed an amended Schedule 13G, revealing a beneficial ownership of 11.21% in CERUS Corp's common stock as of December 31, 2024.